Cargando…

Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients

Objective: The primary objectives of this study were to evaluate the pharmacokinetics (PK) and tolerability of single and multiple doses of vortioxetine in children and adolescents with a depressive or anxiety disorder and to provide supportive information for appropriate dosing regimens for pediatr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Findling, Robert L., Robb, Adelaide S., DelBello, Melissa, Huss, Michael, McNamara, Nora, Sarkis, Elias, Scheffer, Russell, Poulsen, Lis H., Chen, Grace, Lemming, Ole Michael, Areberg, Johan, Auby, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568018/ https://www.ncbi.nlm.nih.gov/pubmed/28333546 http://dx.doi.org/10.1089/cap.2016.0155

Ejemplares similares

A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders
por: Findling, Robert L., et al.
Publicado: (2018)

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
por: Chen, Grace, et al.
Publicado: (2017)

Population Pharmacokinetic Meta-Analysis of Vortioxetine in Healthy Individuals
por: Areberg, Johan, et al.
Publicado: (2014)

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
por: Miao, Jia, et al.
Publicado: (2019)

Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data
por: Frederiksen, Trine, et al.
Publicado: (2021)

Quantification of In Vivo Metabolic Activity of CYP2D6 Genotypes and Alleles Through Population Pharmacokinetic Analysis of Vortioxetine
por: Frederiksen, Trine, et al.
Publicado: (2020)

Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men
por: Wilson, Sue, et al.
Publicado: (2015)

Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium
por: Chen, Grace, et al.
Publicado: (2016)

Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant
por: Chen, Grace, et al.
Publicado: (2013)

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study
por: Vieta, Eduard, et al.
Publicado: (2019)

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study
por: Rancans, Elmars, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Tolerability of Vortioxetine Following Single‐ and Multiple‐Dose Administration in Healthy Japanese Adults
por: Matsuno, Kumi, et al.
Publicado: (2017)

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

Vortioxetine as adjunctive therapy in the treatment of schizophrenia
por: Redaelli, Sofia, et al.
Publicado: (2022)

Clinical effectiveness of vortioxetine in postcovid syndrome
por: Vikarenko, M., et al.
Publicado: (2022)

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine†
por: Montgomery, Stuart A, et al.
Publicado: (2014)

Crystal structures of vortioxetine and its methanol monosolvate
por: Zhou, Xin-Bo, et al.
Publicado: (2015)

Which Cognitive Domains are Improved by Treatment with Vortioxetine?
por: Harrison, John E, et al.
Publicado: (2016)

Vortioxetine improves cognition in mild cognitive impairment
por: Tan, Sheng Neng, et al.
Publicado: (2021)

RisksAssociated with Vortioxetine in the Established Therapeutic Indication
por: Verma, Akansha, et al.
Publicado: (2021)

Vortioxetine Improved Depressive State In Parkinson’s Disease
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Clinical efficacy of Vortioxetine and escitalopram in the treatment of depression
por: Shao, Shichuan, et al.
Publicado: (2022)

Potential Effect of Vortioxetine on Restless Leg Syndrome
por: Alıcı, Yasemin Hoşgören, et al.
Publicado: (2023)

Broad Serotonergic Actions of Vortioxetine as a Promising Avenue for the Treatment of L-DOPA-Induced Dyskinesia
por: Budrow, Carla, et al.
Publicado: (2023)

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
por: Cao, Bing, et al.
Publicado: (2019)

Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data
por: Post, Robert M., et al.
Publicado: (2020)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez, Enric, et al.
Publicado: (2014)

Vortioxetine overdose in a suicidal attempt: A case report
por: Mazza, Mario Gennaro, et al.
Publicado: (2018)

Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents
por: Waller, Jessica A., et al.
Publicado: (2017)

Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial
por: Mills, Natalie T, et al.
Publicado: (2020)

Cognitive effects of vortioxetine in older adults: a systematic review
por: Bishop, Makenna M., et al.
Publicado: (2021)

Vortioxetine Induced Hypomania: A Case Presentation and Review of the Literature
por: Tunc, Ece Buyuksandalyaci, et al.
Publicado: (2022)

Withdrawal Symptoms Following Discontinuation of Vortioxetine—Retrospective Chart Review
por: Siwek, Marcin, et al.
Publicado: (2021)

Effects of Vortioxetine on Sleep Architecture of Adolescents with Major Depressive Disorder
por: Mlyncekova, Zuzana, et al.
Publicado: (2023)

Cytochrome P450 2D6 genotype–phenotype characterization through population pharmacokinetic modeling of tedatioxetine
por: Frederiksen, Trine, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of SHP465 Mixed Amphetamine Salts After Administration of Multiple Daily Doses in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder
por: Ilic, Katarina, et al.
Publicado: (2021)

Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modeling of Brexpiprazole
por: Frederiksen, Trine, et al.
Publicado: (2022)

Impact of Vortioxetine on Synaptic Integration in Prefrontal-Subcortical Circuits: Comparisons with Escitalopram
por: Chakroborty, Shreaya, et al.
Publicado: (2017)

PS110. Reversal of stress-induced anhedonia by the multimodel antidepressant, vortioxetine
por: Christensen, AK, et al.
Publicado: (2016)

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder
por: Florea, Ioana, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c4dce6osjrf2gvmr3fudqqohn6